This is a standard retention tool for a biotech approaching catalysts — no departure or appointment signal. Monitor upcoming catalyst readouts for the real stock-moving events; the retention program itself has no trading implications.
Price Chart
Executive Summary
Karyopharm Therapeutics implemented a 2026 Leadership Cash Retention Program providing lump-sum cash awards totaling $3.715 million to its CEO, CFO, and two other named executive officers. The program replaces the 2026 Annual Bonus Plan and is designed to retain key personnel through an upcoming catalyst period, with awards subject to clawback if employment terminates before 12 months (or 30 days post-change-of-control). This is a routine compensatory arrangement with no departure or appointment of officers — neutral for the stock.
Key Facts
- CEO Richard Paulson receives $1,725,000 retention award
- CFO Lori Macomber receives $625,000 retention award
- Total retention awards to named executive officers: $3,715,000
- Program replaces previously guaranteed 2026 Annual Bonus Plan amounts
- Awards subject to clawback if employment ends before 12 months (or 30 days post-change-of-control) for reasons other than without-cause termination, good reason resignation, death, or permanent disability
- Retention awards reduce amounts payable under existing severance arrangements
Financial Impact
$3.715 million in aggregate cash retention awards to four named executive officers
Risk Factors
- Retention awards may not prevent key departure if catalyst results are negative
- Cash outlay of $3.715M reduces cash runway modestly
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-307964 |
| Document: 0001193125-26-307964-index-headers.html | 0001193125-26-307964 |
| Document: 0001193125-26-307964-index.html | 0001193125-26-307964 |
| Document: 0001193125-26-307964.txt | 0001193125-26-307964 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $1.61 $1.88 | ▼ −16.77% | ▼ −16.99% | $0.8050 (+50.00%) |
Aug 31, 2026 4w ago | 8-K | $2.06 $1.72 | ▼ −16.50% | ▼ −16.36% | $0.8050 (−60.92%) |
Aug 13, 2026 7w ago | 8-K | $1.99 $1.82 | ▲ +8.54% | ▲ +6.58% | $0.8050 (+59.55%) |
Aug 10, 2026 7w ago | Press Release | $1.96 $1.81 | ▼ −7.65% | ▼ −7.61% | $0.8050 (−58.93%) |
Jul 31, 2026 9w ago | 8-K | $1.92 $2.12 | ▲ +10.42% | ▲ +6.91% | $0.8050 (−58.07%) |
Jul 17, 2026 10w ago | 8-K | $7.47 $7.41 | ▼ −0.80% | ▼ −0.38% | $0.8050 (−89.22%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▼ −25.63% | ▼ −24.01% | $0.8050 (+88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access